Using genetic markers to predict prostate cancer outcomes
Predicting prostate cancer clinical outcomes with germline genomic biomarkers
This study is looking at how your genes might help doctors understand the likely outcomes of prostate cancer, so they can better tell if it’s a slow-growing or aggressive type, which could lead to more personalized treatment options for men facing this condition.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of California Los Angeles NIH-funded |
| Lab location | 1 site (Los Angeles, United States) |
| Project ID | NIH-11080750 on NIH RePORTER |
What this research studies
This research investigates how genetic factors can help predict the clinical outcomes of prostate cancer in men. It aims to improve the accuracy of risk assessments by examining hereditary factors, particularly focusing on DNA damage repair genes and genetic ancestry. By identifying specific genetic markers, the study seeks to differentiate between indolent and aggressive forms of localized prostate cancer, potentially leading to better treatment decisions for patients. The research will involve analyzing patient data and genetic information to enhance current clinical practices.
Who could benefit from this research
Good fit: Ideal candidates for this research include American men diagnosed with localized prostate cancer, particularly those with a family history of the disease.
Not a fit: Patients with advanced prostate cancer or those who do not have a genetic predisposition to the disease may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to more accurate predictions of prostate cancer progression, allowing for personalized treatment plans and reducing unnecessary overtreatment.
How similar studies have performed: Previous research has shown promise in using genetic markers for cancer prognosis, indicating that this approach could lead to significant advancements in prostate cancer management.
Where this research is happening
Los Angeles, United States
- University of California Los Angeles — Los Angeles, United States (Active)
Researchers
- Principal investigator: Zeltser, Nicole — University of California Los Angeles
- Study coordinator: Zeltser, Nicole
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.